Key result
Overexpression of Zinc finger antiviral protein (ZAP) in mice significantly increased resistance to coxsackievirus B3 replication and protected against acute viral myocarditis.
Why the study?
Does Zinc finger antiviral protein (ZAP) overexpression inhibit coxsackievirus B3 replication and protect against viral myocarditis in preclinical models?
Does Zinc finger antiviral protein (ZAP) overexpression inhibit coxsackievirus B3 replication and protect against viral myocarditis in preclinical models?
ZAP confers resistance to CVB3 infection and protects mice from acute viral myocarditis, identifying it as a potential therapeutic target.
ZAP protection in mice does not yet inform practice; leaves open its therapeutic potential in human viral myocarditis.
The host Zinc finger antiviral protein (ZAP) has been reported exhibiting antiviral activity against positive-stranded RNA viruses (Togaviridae), negative-stranded RNA viruses (Filoviridae) and retroviruses (Retroviridae). However, whether ZAP restricts the infection of enterovirus and the development of enterovirus mediated disease remains unknown. Here, we reported the antiviral properties of ZAP against coxsackievirus B3 (CVB3), a single-stranded RNA virus of the Enterovirus genus within the Picornaviridae as a major causative agent of viral myocarditis (VMC). We found that the expression of ZAP was significantly induced after CVB3 infection in heart tissues of VMC mice. ZAP potently inhibited CVB3 replication in cells after infection, while overexpression of ZAP in mice significantly increased the resistance to CVB3 replication and viral myocarditis by significantly reducing cardiac inflammatory cytokine production. The ZAP-responsive elements (ZREs) were mapped to the 3'UTR and 5'UTR of viral RNA. Taken together, ZAP confers resistance to CVB3 infection via directly targeting viral RNA and protects mice from acute myocarditis by suppressing viral replication and cardiac inflammatory cytokine production. Our finding further expands ZAP's range of viral targets, and suggests ZAP as a potential therapeutic target for viral myocarditis caused by CVB3.
No takes yet. Share an insight, caveat, or question.
Li et al. (2015) studied Viral myocarditis (Coxsackievirus B3 infection). Zinc finger antiviral protein (ZAP) overexpression was evaluated on CVB3 replication and cardiac inflammatory cytokine production. Overexpression of Zinc finger antiviral protein (ZAP) in mice significantly increased resistance to coxsackievirus B3 replication and protected against acute viral myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: